In 2003, an estimated 1.3 million people in the U.S. will be diagnosed with cancer and 1 in 4 deaths will be due to the disease.  In addition to the tragic human toll, the cost of fighting cancer exceeds $171 billion annually in the U.S.; of this, more than $12 billion is spent on sophisticated products to treat the disease and manage its complications and side effects.  These products include anticancer drugs and biopharmaceuticals; radiotherapy and photodynamic therapy products, cryoablation and radiofrequency ablation systems; and devices used to deliver drugs and nutritional therapies.

This dynamic report from Medtech Insight includes analyses of products, technologies, current and forecast markets, competitors, and opportunities in U.S. markets for therapeutic oncology drugs and devices. 

Covered topics in this report include anti-angiogenesis/vascular targeting agents; anticancer drugs and biopharmaceuticals; anticancer agents in development; cancer incidence, prevalence, and mortality statistics; chemotherapy delivery; cobalt-60 radiotherapy systems; cryoablation systems; endoscopic, laparoscopic, and radioimmunoguided surgery techniques; enteral nutrition delivery products; linear accelerator radiotherapy systems; microwave and radiofrequency ablation systems; oncology-related drug/nutritional therapy delivery products; permanent and temporary implantation brachytherapy products; stem cell transplantation therapy; stereotactic radiosurgery, and therapeutic apheresis.

TABLE OF CONTENTS

EXECUTIVE SUMMARY

i.   Cancer Incidence, Prevalence, and Mortality in the United States

ii.   Emerging and Established Cancer Treatment Approaches

a.  Surgical Intervention

b.  Chemotherapy

c.  Directed Energy-Based Cancer Treatment Modalities

d.  Interventional Radiology

e.  Photodynamic Therapy

f.   Hematologic Therapies

g.  Pain Management and Nutritional Support for Cancer Patients

iii.  Markets for Cancer Treatment and Oncology-Related Drug/Nutritional Therapy Delivery Products

a.  Anticancer Drugs

b.  Radiation Therapy Products

i.      Linear Accelerator Radiotherapy Products

ii.     Gamma Knife Systems

iii.    Cobalt-60 Radiotherapy Systems

iv.    Permanent Implantation Brachytherapy Products

v.     Temporary Implantation Brachytherapy Products

vi.    Cryoablation and Radiofrequency Tumor Ablation Products

vii.   Photodynamic Therapy Products

viii.   Oncology-Related Drug/Nutritional Support Delivery Products

1. CANCER ETIOLOGY AND EPIDEMIOLOGY

1.1 Causes of Cancer

1.2 Incidence and Prevalence of Cancer

1.3 The Cost of Cancer

1.4 Types of Cancer

1.4.1 Bladder Cancer

1.4.1.1 Etiology

1.4.1.2 Epidemiology

1.4.2 Brain/Nervous System Cancer

1.4.2.1 Etiology

1.4.2.2 Epidemiology

1.4.3 Breast Cancer

1.4.3.1 Etiology

1.4.3.2 Epidemiology

1.4.4 Colon/Rectal Cancer

1.4.4.1 Etiology

1.4.4.2 Epidemiology

1.4.5 Leukemia

1.4.5.1 Etiology

1.4.5.2 Epidemiology

1.4.6 Lung/Bronchus Cancer

1.4.6.1 Etiology

1.4.6.2 Epidemiology

1.4.7 Lymphoma

1.4.7.1 Etiology

1.4.7.2 Epidemiology

1.4.8 Malignant Melanoma

1.4.8.1 Etiology

1.4.8.2 Epidemiology

1.4.9 Oral Cavity and Oropharyngeal Cancer

1.4.9.1 Etiology

1.4.9.2 Epidemiology

1.4.10 Ovarian Cancer

1.4.10.1 Etiology

1.4.10.2 Epidemiology

1.4.11 Pancreatic Cancer

1.4.11.1 Etiology

1.4.11.2 Epidemiology

1.4.12 Prostate Cancer

1.4.12.1 Etiology

1.4.12.2 Epidemiology

1.4.13 Uterine/Cervical Cancer

1.4.13.1 Etiology

1.4.13.2 Epidemiology

2. EMERGING AND ESTABLISHED CANCER TREATMENT APPROACHES

2.1 Surgical Intervention

2.1.1 Endoscopic/Laparoscopic Surgical Techniques

2.1.2 Radioimmunoguided Surgery

2.2 Chemotherapy

2.2.1 Anticancer Pharmaceuticals

2.2.1.1 Alkylating Agents

2.2.1.2 Cytotoxic Antibiotics

2.2.1.3 Antimetabolites

2.2.1.4 Platinum Derivatives

2.2.1.5 Nitrosoureas

2.2.1.6 Naturally Occurring Mitotic Inhibitors

2.2.1.7 Camptothecins

2.2.1.8 Hormone Antagonists

2.2.2 Anticancer Biopharmaceuticals

2.2.2.1 Therapeutic Proteins

2.2.2.2 Antibody-Based Therapies

2.2.2.2.1 Naked Monoclonal Antibodies Used in Cancer Management

2.2.2.2.2 Labeled Monoclonal Antibodies Used in Cancer Management

2.2.2.3 Anti-Angiogenic Therapies

2.2.3 Anticancer Pharmaceuticals/Biopharmaceuticals and Angiogenesis Inhibitors in Development

2.2.4 Chemotherapy Delivery

2.2.4.1 Bolus or Drip Infusion

2.2.4.2 Continuous Infusion

2.2.4.3 Circadian Rhythm Therapy

2.2.4.4 Biodegradable Implants/Injectable Sustained-Release Formulations

2.2.4.5 Chemotherapy Delivery-Enhancing Devices

2.2.5 Chemotherapy Regimens

2.2.5.1 Single-Agent Treatment

2.2.5.2 Combination Treatment

2.2.5.3 High-Dose Chemotherapy Regimens

2.2.6 Adverse Effects and Response Failure Associated with Chemotherapeutics

2.2.6.1 Adjuvant and Neoadjuvant Chemotherapy

2.2.6.2 Dose Intensification

2.2.6.3 Resistance Modification

2.3 Directed Energy-Based Cancer Treatment Modalities

2.3.1 Radiation Therapy

2.3.1.1 External Beam Radiation Therapy

2.3.1.1.1 Cobalt-60 Machines

2.3.1.1.2 Gamma Knife Systems

2.3.1.1.3 Linear Accelerators

2.3.1.1.3.1 Conformal and Intensity Modulated Radiation Therapies

2.3.1.1.3.2 Stereotactic Radiosurgery

2.3.1.1.4 Support Products and Services

2.3.1.1.4.1 Alignment Systems, and Test Equipment and Accessories

2.3.1.1.4.2 Service Contracts

2.3.1.1.4.3 Treatment Planning Systems

2.3.1.2 Brachytherapy

2.3.1.2.1 Permanent Implantation Brachytherapy

2.3.1.2.2 Temporary Implantation Brachytherapy

2.3.1.2.2.1 Remote Afterloading Techniques

2.3.2 Alternative Directed Energy-Based Cancer Therapies

2.3.2.1 Cryoablation

2.3.2.2 Laser-Based Surgery

2.3.2.2.1 Emerging Oncologic Applications of Laser Ablation Techniques

2.3.2.3 Radiofrequency and Microwave Ablation

2.3.2.3.1 Clinical Experience with Radiofrequency Tumor Ablation

2.3.2.3.2 Radiofrequency Ablation Systems

2.3.2.3.3 Microwave Ablation Systems Under Development

2.3.2.4 High-Intensity Focused Ultrasound-Based Surgery

2.4 Interventional Radiology

2.4.1 Conventional Embolization

2.4.2 Chemoembolization

2.4.3 Radioembolization

2.4.4 Stent-Based Palliation of Malignant Circulatory Obstructions

2.5 Photodynamic Therapy

2.5.1 Principles and Mechanisms of Oncologic Photodynamic Therapy

2.5.2 Photodynamic Therapy versus Leading Cancer Treatment Modalities

2.6 Hematologic Therapies

2.6.1 Therapeutic Apheresis

2.6.1.1 Types of Therapeutic Apheresis

2.6.1.2 Oncology-Related Applications of Therapeutic Apheresis

2.6.2 Stem Cell Transplantation

2.6.2.1 Bone Marrow Transplantation

2.6.2.1.1 Types of Bone Marrow Transplantation

2.6.2.1.2 Delayed Side Effects of Bone Marrow Transplantation

2.6.2.1.3 Oncology-Related Applications of Bone Marrow Transplantation

2.6.2.2 Peripheral Blood Stem Cell Transplantation

2.6.2.2.1 Peripheral Blood Stem Cell Collection and Purging Techniques

2.6.2.2.3 Mobilized Peripheral Blood

2.6.2.2.4 Umbilical Cord Blood as a Stem Cell Source

2.6.2.2.5 Oncology-Related Applications of Stem Cell Therapy

2.7 Pain Management and Nutritional Support for Cancer Patients

2.7.1 Pain Management for Cancer Patients

2.7.1.1 Causes and Incidence of Cancer-Related Pain

2.7.1.2 Methods of Managing Cancer Pain

2.7.1.2.1 Treatment of Underlying Malignancy

2.7.1.2.2 Administration of Pain Management Pharmaceuticals

2.7.1.2.3 Nerve Block

2.7.1.2.4 Use of Complementary and Alternative Medicine Techniques

2.7.2 Nutritional Support for Cancer Patients

2.7.2.1 Total Parenteral Nutrition

2.7.2.2 Enteral Nutrition Therapy

3. MARKETS FOR CANCER TREATMENT AND ONCOLOGY-RELATED DRUG/NUTRITIONAL THERAPY DELIVERY PRODUCTS

3.1 Anticancer Drugs

3.1.1 Market Forecast

3.1.2 Competitive Analysis

3.2 Radiation Therapy Products

3.2.1 Linear Accelerator Radiotherapy Products

3.2.1.1 Market Analysis

3.2.1.2 Competitive Analysis

3.2.2 Gamma Knife Systems

3.2.2.1 Market Analysis

3.2.3 Cobalt-60 Radiotherapy Systems

3.2.3.1 Market Forecast

3.2.4 Permanent Implantation Brachytherapy Products

3.2.4.1 Market Forecast

3.2.4.2 Competitive Analysis

3.2.5 Temporary Implantation Brachytherapy Products

3.2.5.1 Market Forecast

3.2.5.2 Competitive Analysis

3.3 Cryoablation and Radiofrequency Tumor Ablation Products

3.3.1 Market Forecast

3.3.2 Competitive Analysis

3.4 Photodynamic Therapy Products

3.4.1 Market Forecast

3.4.2 Competitive Analysis

3.5 Oncology-Related Drug/Nutritional Support Delivery Products

3.5.1 Vascular Access Devices and Infusion Pumps for Oncology-Related Drug/Total Parenteral Nutrition Delivery

3.5.1.1 Central Venous Catheters

3.5.1.2 Peripherally Inserted Central Venous Catheters

3.5.1.3 Implantable Ports

3.5.1.4 Volumetric Pumps

3.5.1.5 Syringe Pumps

3.5.1.6 Ambulatory Pumps

3.5.1.7 Implantable Pumps

3.5.1.8 Market Forecast

3.5.2 Pumps and Gravity Systems for Oncology-Related Enteral Nutrition Delivery

3.5.2.1 Enteral Nutrition Pumps and Sets

3.5.2.2 Disposable Gravity Systems

3.5.2.3 Market Forecast

4. COMPANY PROFILES

4.1   Abbott Laboratories

4.2   Amersham Group

4.3   Amgen, Inc.

4.4   AstraZeneca PLC

4.5   Aventis SA

4.6   Axcan Pharma, Inc.

4.7   C.R. Bard, Inc.

4.8   Baxter International, Inc.

4.9   Bristol-Myers Squibb Company

4.10 Elekta Group

4.11 Endocare, Inc.

4.12 Genentech, Inc.

4.13 GlaxoSmithKline PLC

4.14 MDS, Inc.

4.15 Microsulis LTD

4.16 Novartis AG

4.17 Nucletron Corporation/Nucletron BV/Delft Instruments NV

4.18 Pfizer, Inc.

4.19 RITA Medical Systems, Inc.

4.20 Siemens AG

4.21 Tyco International LTD

4.22 Varian Medical Systems, Inc.

4.23 Vivant Medical, Inc.

APPENDIX:  COMPANY LISTING

LIST OF EXHIBITS

Exhibit ES-1:    2002, Cancer Incidence, Prevalence, and Mortality, by Site

Exhibit ES-2:    Anticancer Drugs, Market Forecast, 2002-2007

Exhibit ES-3:    Radiation Therapy Products, Market Forecast, 2002-2007

Exhibit ES-4:    Linear Accelerator Radiotherapy Products, Market Forecast, 2002-2007

Exhibit ES-5:    Gamma Knife Radiosurgery Systems, Market Forecast, 2002-2007

Exhibit ES-6:    Cobalt-60 Radiotherapy Systems, Market Forecast, 2002-2007

Exhibit ES-7:    Permanent Implantation Brachytherapy Products, Market Forecast, 2002-2007

Exhibit ES-8:    Temporary Implantation Brachytherapy Products, Market Forecast, 2002-2007

Exhibit ES-9:    Cryoablation and Radiofrequency Tumor Ablation Products, Market Forecast, 2002-2007

Exhibit ES-10:   Oncology-Related Photodynamic Therapy Products, Market Forecast, 2002-2007

Exhibit ES-11:   Oncology-Related Drug/Total Parenteral Nutrition Delivery Products, Market Forecast, 2002-2007

Exhibit ES-12:   Oncology-Related Enteral Nutrition Delivery Products, Market Forecast, 2000-2005

Exhibit 1-1:      2002, Cancer Incidence, Prevalence, and Mortality, by Site

Exhibit 1-2:      2002, Bladder Cancer, Facts and Figures

Exhibit 1-3:      2002, Brain Cancer, Facts And Figures

Exhibit 1-4:      2002, Breast Cancer, Facts And Figures

Exhibit 1-5:      2002, Colon/Rectal Cancer, Facts And Figures

Exhibit 1-6:      2002, Leukemia, Facts and Figures

Exhibit 1-7:      2002, Lung/Bronchus Cancer, Facts And Figures

Exhibit 1-8:      2002, Lymphoma, Facts and Figures

Exhibit 1-9:      2002, Malignant Melanoma, Facts and Figures

Exhibit 1-10:     2002, Oral Cavity and Oropharyngeal Cancer, Facts and Figures

Exhibit 1-11:     2002, Ovarian Cancer, Facts and Figures

Exhibit 1-12:     2002, Pancreatic Cancer, Facts and Figures

Exhibit 1-13:     2002, Prostate Cancer, Facts And Figures

Exhibit 1-14:     2002, Uterine/Cervical Cancer, Facts and Figures

Exhibit 2-1:      2003, Selected Anticancer Pharmaceuticals

Exhibit 2-2:      2003, Selected Anticancer Pharmaceuticals/Biopharmaceuticals and Angiogenesis Inhibitors in Development

Exhibit 2-3:      Advantages and Disadvantages of Photodynamic Therapy for Cancer Indications

Exhibit 2-4:      Types and Goals of Selected Therapeutic Apheresis Procedures

Exhibit 2-5:      2003, Selected Techniques and Processes Used to Purge Bone Marrow and Peripheral Blood Stem Cell Collections of Tumor Cells

Exhibit 2-6:      The World Health Organization’s Three-Step Analgesic Ladder

Exhibit 3-1:      Cancer Treatment and Oncology-Related Drug/Nutritional Therapy Delivery Products, Market Forecast, 2002-2007

Exhibit 3-2:      2002, Indications and Estimated Global Sales for Selected Anticancer Drugs

Exhibit 3-3:      Anticancer Drugs, Market Forecast, 2002-2007

Exhibit 3-4:      2002, Anticancer Drugs Market, Share by Supplier

Exhibit 3-5:      Radiation Therapy Products, Market Forecast, 2002-2007

Exhibit 3-6:      2003, Selected Linear Accelerator Radiotherapy Products

Exhibit 3-7:      Linear Accelerator Radiotherapy Products, Market Forecast, 2002-2007

Exhibit 3-8:      2002, Linear Accelerator Radiotherapy Systems Market, Share by Supplier

Exhibit 3-9:      2003, Selected Gamma Knife Radiosurgery Products

Exhibit 3-10:     Gamma Knife Radiosurgery Systems, Market Forecast, 2002-2007

Exhibit 3-11:     2003, Selected Cobalt-60 Radiotherapy Systems

Exhibit 3-12:     Cobalt-60 Radiotherapy Systems, Market Forecast, 2002-2007

Exhibit 3-13:     2003, Selected Permanent Implantation Brachytherapy Radioisotope Seeds

Exhibit 3-14:     Permanent Implantation Brachytherapy Products, Market Forecast, 2002-2007

Exhibit 3-15:     2002, Permanent Implantation Brachytherapy Products Market, Share by Supplier

Exhibit 3-16:     2003, Selected Temporary Implantation Brachytherapy Products

Exhibit 3-17:     Temporary Implantation Brachytherapy Products, Market Forecast, 2002-2007

Exhibit 3-18:     2002, Temporary Implantation Brachytherapy Products Market, Share by Supplier

Exhibit 3-19:     2003, Selected Cryoablation and Radiofrequency Tumor Ablation Systems

Exhibit 3-20:     Cryoablation and Radiofrequency Tumor Ablation Products, Market Forecast, 2002-2007

Exhibit 3-21:     2002, Cryoablation and Radiofrequency Tumor Ablation Products Market, Share by Supplier

Exhibit 3-22:     2003, Selected Photodynamic Therapy Products

Exhibit 3-23:     Oncology-Related Photodynamic Therapy Products, Market Forecast, 2002-2007

Exhibit 3-24:     2002, Oncology-Related Photodynamic Therapy Products Market,  Share by Supplier

Exhibit 3-25:     Oncology-Related Drug/Nutritional Support Delivery Products, Market Forecast, 2002-2007

Exhibit 3-26:     Oncology-Related Drug/Total Parenteral Nutrition Support, Caseload Forecast, 2002-2007

Exhibit 3-27:     Oncology-Related Drug/Total Parenteral Nutrition Delivery Products, Market Forecast, 2002-2007

Exhibit 3-28:     Oncology-Related Enteral Nutrition Therapy, Caseload Forecast, 2002-2007

Exhibit 3-29:     Oncology-Related Enteral Nutrition Delivery Products, Market Forecast, 2000-2005

Copyright 2003, Medtech Insight, LLC